Researchers are making progress in understanding the biological mechanisms behind Sjögren’s disease, an autoimmune disorder that primarily affects the salivary and lacrimal glands, leading to symptoms such as dry eyes and dry mouth. Recent findings highlight the critical role of impaired regulatory T cells and dysregulated interferon signaling in driving the disease process, both in animal models and in human patients.
The insights arrive from a study investigating the function of stromal interaction proteins (STIM) 1 and 2 in regulatory T cells. Scientists observed that mice with T cell-specific deletion of STIM1 and STIM2 developed a Sjögren’s-like disorder characterized by inflammation and dysfunction in the salivary and lacrimal glands, along with the production of autoantibodies and extraglandular manifestations. These findings were supported by histological analysis, RNA sequencing, and flow cytometry of affected tissues.
Further analysis revealed that the salivary gland inflammation in these mice was marked by infiltration of T and B cells and a transcriptional profile consistent with a T helper 1 (Th1) immune response. This Th1 signature, particularly the production of interferon-gamma (IFN-γ) by CD4+ T cells, closely resembled patterns seen in human patients with Sjögren’s disease. The study demonstrated that transferring effector T cells from the modified mice into immunodeficient recipients was sufficient to induce disease symptoms, indicating that IFN-γ-producing autoreactive T cells can drive pathogenesis independently of B cells and autoantibodies.
In parallel, single-cell transcriptomic analysis of peripheral blood mononuclear cells from patients with Sjögren’s disease and healthy controls confirmed a Th1-skewed immune response and dysregulation in regulatory T cell function in human samples. These results suggest that defects in calcium signaling within regulatory T cells may impair their ability to suppress autoreactive immune responses, thereby promoting chronic inflammation and tissue damage in Sjögren’s disease.
The research also points to a potential therapeutic avenue. Since the disease mechanism involves heightened IFN-γ signaling, existing drugs that modulate this pathway—such as janus kinase (JAK) inhibitors used in other rheumatological conditions—are being considered as possible repurposed treatments for Sjögren’s disease. Yet, experts emphasize that clinical trials would be necessary to determine the safety and efficacy of such approaches in this specific patient population.
While the exact triggers of Sjögren’s disease remain unclear, the condition is known to affect millions worldwide, with a significantly higher prevalence in women. Beyond ocular and oral dryness, patients may experience fatigue, joint pain, and an increased risk of lymphoma. Current management focuses on symptom relief through artificial tears, saliva substitutes, and immunosuppressive therapies in severe cases, but no curative treatment exists.
As research continues to unravel the immune dysregulation underlying Sjögren’s disease, scientists hope that targeting specific pathways—like the STIM-dependent regulation of T cell function or IFN-γ signaling—could lead to more precise and effective therapies. Ongoing efforts aim to translate these mechanistic insights into clinical applications that improve long-term outcomes for individuals living with this chronic autoimmune condition.
The next step in this research involves further validation of these mechanisms in larger human cohorts and exploration of clinical trials targeting interferon pathways. For updates on ongoing studies, readers can refer to clinical trial registries such as ClinicalTrials.gov.
Share your thoughts on this development in the comments below, and help spread awareness by sharing this article with others who may find it informative.